Screener
PTC Therapeutics PTCT Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Selling, general and administrative | 86,183 | 80,961 |
| Change in the fair value of contingent consideration | — | (800) |
| Tangible asset impairment and losses on transactions, net | 927 | 77 |
| Total operating expenses | 227,592 | 205,871 |
| Income from operations | 44,959 | 970,225 |
| Interest expense, net | (49,030) | (34,092) |
| Other income (expense), net | 1,609 | (6,305) |
| (Loss) income before income tax expense | (2,462) | 929,828 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's other operating expenses?
- PTC Therapeutics (PTCT) reported other operating expenses of $227.59M in Q1 2026.
- How has PTC Therapeutics's other operating expenses changed year-over-year?
- PTC Therapeutics's other operating expenses increased by 10.6% year-over-year, from $205.87M to $227.59M.
- What is the long-term trend for PTC Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), PTC Therapeutics's other operating expenses has grown at a -1.4% compound annual growth rate (CAGR), from $913.04M to $863.72M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about PTC Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude